{"brief_title": "Sitosterolemia Extension Study (0653-003)(COMPLETED)", "brief_summary": "This is an extension study for patients having unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases. This study will evaluate the long term safety and the ability to lower cholesterol levels with an investigational drug.", "detailed_description": "The duration of treatment is 52 weeks.", "condition": ["Lipid Metabolism, Inborn Errors", "Heart Disease"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["MK0653, ezetimibe", "Comparator: placebo"], "criteria": "Inclusion Criteria: - Patients with elevated sitosterol levels while taking current medication Exclusion Criteria: - Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.", "gender": "All", "minimum_age": "10 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Homozygous Sitosterolemia", "mesh_term": ["Heart Diseases", "Metabolism, Inborn Errors", "Lipid Metabolism, Inborn Errors", "Ezetimibe"], "id": "NCT00092807"}